Details of the Drug

General Information of Drug (ID: DMGFPU2)

• Drug Name: Linezolid
• Synonyms: Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017

Indication

Disease Entry	ICD 11	Status	REF
Bacteremia	1A73	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Staphylococcal pneumonia	N.A.	Approved	[1]
Staphylococcus aureus infection	N.A.	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]
Skin infection	1F28-1G0Z	Investigative	[1]

• Therapeutic Class: Antibiotics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 337.35
  Logarithm of the Partition Coefficient (xlogp); 0.7
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.8 mL/min/kg [6]
  Elimination: 30% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4.5 hours [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 50.8162 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.69% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.58 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 8 mg/mL [4]
• Chemical Identifiers:
  Formula: C16H20FN3O4
  IUPAC Name: N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
  Canonical SMILES: CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
  InChI: InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
  InChIKey: TYZROVQLWOKYKF-ZDUSSCGKSA-N
• Cross-matching ID:
  PubChem CID: 441401
  ChEBI ID: CHEBI:63607
  CAS Number: 165800-03-3
  DrugBank ID: DB00601
  TTD ID: D07UYO
  VARIDT ID: DR00748
  ACDINA ID: D00367
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA)	TTLFGBV	NOUNIPROTAC	Binder	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Gene/Protein Processing	[9]
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Gene/Protein Processing	[9]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Linezolid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Linezolid and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[10]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Repaglinide.	Acute diabete complication [5A2Y]	[11]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Glibenclamide.	Acute diabete complication [5A2Y]	[11]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Tolazamide.	Acute diabete complication [5A2Y]	[11]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Nateglinide.	Acute diabete complication [5A2Y]	[11]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Insulin-glulisine.	Acute diabete complication [5A2Y]	[11]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Insulin-aspart.	Acute diabete complication [5A2Y]	[12]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Glipizide.	Acute diabete complication [5A2Y]	[11]
Epinephrine	DM3KJBC	Major	Additive hypertensive effects by the combination of Linezolid and Epinephrine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Linezolid and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Linezolid and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Tripelennamine	DMZBU15	Moderate	Additive CNS depression effects by the combination of Linezolid and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Linezolid and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[15]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Linezolid and Trimethaphan.	Aneurysm/dissection [BD50]	[16]
Bepridil	DM0RKS4	Moderate	Additive hypotensive effects by the combination of Linezolid and Bepridil.	Angina pectoris [BA40]	[15]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Linezolid and Amyl nitrite.	Angina pectoris [BA40]	[15]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Linezolid and Nifedipine.	Angina pectoris [BA40]	[15]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Linezolid and Levalbuterol.	Asthma [CA23]	[17]
Terbutaline	DMD4381	Moderate	Additive hypertensive effects by the combination of Linezolid and Terbutaline.	Asthma [CA23]	[18]
Pirbuterol	DMI5678	Moderate	Additive hypertensive effects by the combination of Linezolid and Pirbuterol.	Asthma [CA23]	[18]
Ephedrine	DMMV0KW	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Ephedrine.	Asthma [CA23]	[13]
Salbutamol	DMN9CWF	Moderate	Additive hypertensive effects by the combination of Linezolid and Salbutamol.	Asthma [CA23]	[17]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Roflumilast.	Asthma [CA23]	[19]
Formoterol	DMSOURV	Moderate	Additive hypertensive effects by the combination of Linezolid and Formoterol.	Asthma [CA23]	[18]
Lisdexamfetamine	DM6W8V5	Major	Additive hypertensive effects by the combination of Linezolid and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[15]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Linezolid and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[20]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Linezolid and Droxidopa.	Autonomic nervous system disorder [8D87]	[21]
Pseudoephedrine	DMIVJ0D	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Pseudoephedrine.	Breathing abnormality [MD11]	[13]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Linezolid and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Linezolid and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Salmeterol	DMIEU69	Moderate	Additive hypertensive effects by the combination of Linezolid and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Indacaterol	DMQJHR7	Moderate	Additive hypertensive effects by the combination of Linezolid and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Arformoterol	DMYM974	Moderate	Additive hypertensive effects by the combination of Linezolid and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Linezolid and Levomilnacipran.	Chronic pain [MG30]	[20]
Isoproterenol	DMK7MEY	Moderate	Additive hypertensive effects by the combination of Linezolid and Isoproterenol.	Conduction disorder [BC63]	[17]
Cocaine	DMSOX7I	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Cocaine.	Corneal disease [9A76-9A78]	[22]
Remifentanil	DMZTXCH	Major	Additive serotonergic effects by the combination of Linezolid and Remifentanil.	Corneal disease [9A76-9A78]	[23]
Mycophenolic acid	DMRBMAU	Moderate	Altered absorption of Linezolid due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[24]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Linezolid and Cyclandelate.	Dementia [6D80-6D8Z]	[15]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Linezolid and Sertraline.	Depression [6A70-6A7Z]	[20]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Linezolid and Trimipramine.	Depression [6A70-6A7Z]	[20]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Linezolid and Nefazodone.	Depression [6A70-6A7Z]	[20]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Linezolid and Paroxetine.	Depression [6A70-6A7Z]	[20]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Linezolid and Selegiline.	Depression [6A70-6A7Z]	[25]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Linezolid and Vortioxetine.	Depression [6A70-6A7Z]	[20]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Linezolid and Isocarboxazid.	Depression [6A70-6A7Z]	[25]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Linezolid and Milnacipran.	Depression [6A70-6A7Z]	[20]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Linezolid and Escitalopram.	Depression [6A70-6A7Z]	[20]
Tranylcypromine	DMGB5RE	Major	Additive hypertensive effects by the combination of Linezolid and Tranylcypromine.	Depression [6A70-6A7Z]	[25]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Linezolid and Desvenlafaxine.	Depression [6A70-6A7Z]	[20]
Phenelzine	DMHIDUE	Major	Additive hypertensive effects by the combination of Linezolid and Phenelzine.	Depression [6A70-6A7Z]	[25]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Linezolid and Clomipramine.	Depression [6A70-6A7Z]	[20]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Linezolid and Trazodone.	Depression [6A70-6A7Z]	[20]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Linezolid and Doxepin.	Depression [6A70-6A7Z]	[20]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Linezolid and Maprotiline.	Depression [6A70-6A7Z]	[20]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Linezolid and Esketamine.	Depression [6A70-6A7Z]	[26]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Linezolid and Nitroglycerin.	Diabetic foot ulcer [BD54]	[15]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Linezolid and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[10]
LEVONORDEFRIN	DMWDJ0H	Major	Additive hypertensive effects by the combination of Linezolid and LEVONORDEFRIN.	Discovery agent [N.A.]	[13]
Tetrabenazine	DMYWQ0O	Major	Additive hypertensive effects by the combination of Linezolid and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[27]
Deutetrabenazine	DMUPFLI	Major	Additive hypertensive effects by the combination of Linezolid and Deutetrabenazine.	Dystonic disorder [8A02]	[27]
Oxcarbazepine	DM5PU6O	Major	Additive serotonergic effects by the combination of Linezolid and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[10]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Linezolid and Guanabenz.	Essential hypertension [BA00]	[15]
Guanethidine	DM9NSWT	Moderate	Antagonize the effect of Linezolid when combined with Guanethidine.	Essential hypertension [BA00]	[28]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Linezolid and Nicardipine.	Essential hypertension [BA00]	[15]
Mephentermine	DMFJH5Q	Major	Additive hypertensive effects by the combination of Linezolid and Mephentermine.	Essential hypertension [BA00]	[13]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Linezolid and Mecamylamine.	Essential hypertension [BA00]	[15]
Oxymetazoline	DM8ZXT6	Moderate	Decreased metabolism of Linezolid caused by Oxymetazoline mediated inhibition of non-CYP450 enzyme.	Eyelid inflammatory disorder [9A02]	[29]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Linezolid and Phentolamine.	Gangrene [MC85]	[15]
Ergotamine	DMKR3C5	Major	Additive serotonergic effects by the combination of Linezolid and Ergotamine.	Headache [8A80-8A84]	[23]
Dobutamine	DMD1B8Z	Major	Additive hypertensive effects by the combination of Linezolid and Dobutamine.	Heart failure [BD10-BD1Z]	[13]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Linezolid and Eplerenone.	Heart failure [BD10-BD1Z]	[15]
Nesiritide	DMFOIA8	Moderate	Additive hypotensive effects by the combination of Linezolid and Nesiritide.	Heart failure [BD10-BD1Z]	[15]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Linezolid and Chlorothiazide.	Heart failure [BD10-BD1Z]	[15]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Linezolid and Furosemide.	Heart failure [BD10-BD1Z]	[15]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Linezolid and Bumetanide.	Heart failure [BD10-BD1Z]	[15]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Linezolid and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[15]
Tetrahydrozoline	DMT57WC	Moderate	Decreased metabolism of Linezolid caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme.	Herpes simplex infection [1F00]	[29]
Procarbazine	DMIK367	Major	Additive hypertensive effects by the combination of Linezolid and Procarbazine.	Hodgkin lymphoma [2B30]	[25]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Linezolid and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[30]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Linezolid and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Maraviroc	DMTL94F	Moderate	Additive hypotensive effects by the combination of Linezolid and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Linezolid and Isosorbide mononitrate.	Hydrocephalus [8D64]	[15]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Linezolid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[32]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Linezolid and Eprosartan.	Hypertension [BA00-BA04]	[15]
Aliskiren	DM1BV7W	Moderate	Additive hypotensive effects by the combination of Linezolid and Aliskiren.	Hypertension [BA00-BA04]	[15]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Linezolid and Moexipril.	Hypertension [BA00-BA04]	[15]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Linezolid and Captopril.	Hypertension [BA00-BA04]	[15]
Methyldopa	DM5I621	Major	Decreased metabolism of Linezolid caused by Methyldopa mediated inhibition of non-CYP450 enzyme.	Hypertension [BA00-BA04]	[28]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Linezolid and Losartan.	Hypertension [BA00-BA04]	[15]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Linezolid and Levamlodipine.	Hypertension [BA00-BA04]	[15]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Linezolid and Verapamil.	Hypertension [BA00-BA04]	[15]
Methoxamine	DMF5XQH	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Methoxamine.	Hypertension [BA00-BA04]	[13]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Linezolid and Fenoldopam.	Hypertension [BA00-BA04]	[15]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Linezolid and Indapamide.	Hypertension [BA00-BA04]	[15]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Linezolid and Trichlormethiazide.	Hypertension [BA00-BA04]	[15]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Linezolid and Diazoxide.	Hypertension [BA00-BA04]	[15]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Linezolid and Perindopril.	Hypertension [BA00-BA04]	[15]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Linezolid and Felodipine.	Hypertension [BA00-BA04]	[15]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Linezolid and Quinapril.	Hypertension [BA00-BA04]	[15]
Deserpidine	DMRH7CV	Moderate	Additive hypertensive effects by the combination of Linezolid and Deserpidine.	Hypertension [BA00-BA04]	[33]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Linezolid and Hydralazine.	Hypertension [BA00-BA04]	[15]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Linezolid and Lisinopril.	Hypertension [BA00-BA04]	[15]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Linezolid and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[15]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Linezolid and Clevidipine butyrate.	Hypertension [BA00-BA04]	[15]
Metaraminol	DMWIX23	Major	Additive hypertensive effects by the combination of Linezolid and Metaraminol.	Hypotension [BA20-BA21]	[13]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Linezolid and Propiomazine.	Insomnia [7A00-7A0Z]	[15]
Naphazoline	DMJFZDL	Moderate	Decreased metabolism of Linezolid caused by Naphazoline mediated inhibition of non-CYP450 enzyme.	Itching [1F28-1G07]	[29]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Linezolid and Denosumab.	Low bone mass disorder [FB83]	[34]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Linezolid and Almogran.	Migraine [8A80]	[20]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Linezolid and Frovatriptan.	Migraine [8A80]	[20]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Linezolid and Rizatriptan.	Migraine [8A80]	[20]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Linezolid and Naratriptan.	Migraine [8A80]	[20]
Sumatriptan	DMVYXR8	Major	Additive serotonergic effects by the combination of Linezolid and Sumatriptan.	Migraine [8A80]	[20]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Linezolid and Lasmiditan.	Migraine [8A80]	[20]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Linezolid and Thalidomide.	Multiple myeloma [2A83]	[31]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Tecfidera.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Linezolid and Fingolimod.	Multiple sclerosis [8A40]	[36]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Ocrelizumab.	Multiple sclerosis [8A40]	[37]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Linezolid caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[38]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[39]
Dextroamphetamine	DMMIHVP	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Dextroamphetamine.	Narcolepsy [7A20]	[15]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Linezolid and Phenindamine.	Nasopharyngitis [CA00]	[14]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Linezolid and Promethazine.	Nausea/vomiting [MD90]	[15]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Linezolid and Cyclizine.	Nausea/vomiting [MD90]	[14]
Metoclopramide	DMFA5MY	Moderate	Increased risk of hyperpyrexia by the combination of Linezolid and Metoclopramide.	Nausea/vomiting [MD90]	[40]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Linezolid and Dolasetron.	Nausea/vomiting [MD90]	[14]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Linezolid and Ondansetron.	Nausea/vomiting [MD90]	[14]
Phendimetrazine	DM6TS1N	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Phendimetrazine.	Obesity [5B80-5B81]	[15]
Amfepramone	DM9YSNQ	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Amfepramone.	Obesity [5B80-5B81]	[15]
Benzphetamine	DMIJATC	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Benzphetamine.	Obesity [5B80-5B81]	[15]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Linezolid and Dexfenfluramine.	Obesity [5B80-5B81]	[20]
Propylhexedrine	DMTBW2O	Moderate	Decreased metabolism of Linezolid caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme.	Obesity [5B80-5B81]	[29]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Linezolid and Polythiazide.	Oedema [MG29]	[15]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Linezolid and Lofexidine.	Opioid use disorder [6C43]	[15]
Apraclonidine	DMO4PVE	Major	Additive hypertensive effects by the combination of Linezolid and Apraclonidine.	Optic nerve disorder [9C40]	[33]
Methamphetamine	DMPM4SK	Major	Increased risk of hyperpyrexia by the combination of Linezolid and Methamphetamine.	Pain [MG30-MG3Z]	[41]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Linezolid and Safinamide.	Parkinsonism [8A00]	[25]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Linezolid and Rasagiline.	Parkinsonism [8A00]	[25]
Levodopa	DMN3E57	Major	Additive hypertensive effects by the combination of Linezolid and Levodopa.	Parkinsonism [8A00]	[15]
Dopamine	DMPGUCF	Major	Additive hypertensive effects by the combination of Linezolid and Dopamine.	Parkinsonism [8A00]	[13]
Ritodrine	DM4V6RL	Moderate	Additive hypertensive effects by the combination of Linezolid and Ritodrine.	Preterm labour/delivery [JB00]	[18]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Linezolid and Terazosin.	Prostate hyperplasia [GA90]	[15]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Linezolid and Tamsulosin.	Prostate hyperplasia [GA90]	[15]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Linezolid and Silodosin.	Prostate hyperplasia [GA90]	[15]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Linezolid and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Fluphenazine	DMIT8LX	Moderate	Additive CNS depression effects by the combination of Linezolid and Fluphenazine.	Psychotic disorder [6A20-6A25]	[15]
Selexipag	DMAHSU0	Moderate	Additive hypotensive effects by the combination of Linezolid and Selexipag.	Pulmonary hypertension [BB01]	[15]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Linezolid and Tolazoline.	Pulmonary hypertension [BB01]	[15]
Epoprostenol	DMUTYR2	Moderate	Additive hypotensive effects by the combination of Linezolid and Epoprostenol.	Pulmonary hypertension [BB01]	[15]
Iloprost	DMVPZBE	Moderate	Additive hypotensive effects by the combination of Linezolid and Iloprost.	Pulmonary hypertension [BB01]	[15]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Canakinumab.	Rheumatoid arthritis [FA20]	[42]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Rilonacept.	Rheumatoid arthritis [FA20]	[42]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Linezolid and Golimumab.	Rheumatoid arthritis [FA20]	[43]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Linezolid and Leflunomide.	Rheumatoid arthritis [FA20]	[32]
Mesoridazine	DM2ZGAN	Moderate	Additive CNS depression effects by the combination of Linezolid and Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Moderate	Additive CNS depression effects by the combination of Linezolid and Thioridazine.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Linezolid and Perphenazine.	Schizophrenia [6A20]	[15]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Linezolid and Trifluoperazine.	Schizophrenia [6A20]	[15]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Linezolid and Fentanyl.	Sensation disturbance [MB40]	[44]
Sufentanil	DMU7YEL	Major	Additive serotonergic effects by the combination of Linezolid and Sufentanil.	Sensation disturbance [MB40]	[23]
Avanafil	DM75CXN	Moderate	Additive hypotensive effects by the combination of Linezolid and Avanafil.	Sexual dysfunction [HA00-HA01]	[15]
Tadalafil	DMJZHT1	Moderate	Additive hypotensive effects by the combination of Linezolid and Tadalafil.	Sexual dysfunction [HA00-HA01]	[15]
Vardenafil	DMTBGW8	Moderate	Additive hypotensive effects by the combination of Linezolid and Vardenafil.	Sexual dysfunction [HA00-HA01]	[15]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Linezolid and Papaverine.	Tonus and reflex abnormality [MB47]	[15]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Linezolid and Azathioprine.	Transplant rejection [NE84]	[26]
Mycophenolate mofetil	DMPQAGE	Moderate	Altered absorption of Linezolid due to GI flora changes caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[24]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[11]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[11]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Linezolid and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[11]
Chlorpheniramine	DM5URA2	Moderate	Additive CNS depression effects by the combination of Linezolid and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[14]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Linezolid and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Carbinoxamine	DMCT31R	Moderate	Additive CNS depression effects by the combination of Linezolid and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[14]
Brompheniramine	DMFOVSD	Moderate	Additive CNS depression effects by the combination of Linezolid and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[14]
Xylometazoline	DMKV32D	Moderate	Decreased metabolism of Linezolid caused by Xylometazoline mediated inhibition of non-CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[29]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Linezolid and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[14]
Azatadine	DMZ80SB	Moderate	Additive CNS depression effects by the combination of Linezolid and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[14]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Linezolid and Ganciclovir.	Virus infection [1A24-1D9Z]	[26]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Linezolid and Valganciclovir.	Virus infection [1A24-1D9Z]	[26]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Linezolid 600 mg tablet	600 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Linezolid FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200222.
• [3] Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12.
• [4] BDDCS applied to over 900 drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
• [9] Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.
• [10] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
• [11] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [12] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
• [13] Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK "Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr." J Clin Pharmacol 41 (2001): 563-72. [PMID: 11361053]
• [14] Canadian Pharmacists Association.
• [15] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [16] Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
• [17] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
• [18] Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
• [19] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [20] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
• [21] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [22] Product Information. Cocaine Hydrochloride Nasal (cocaine nasal). Genus Lifesciences Inc., Allentown, PA.
• [23] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [24] Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
• [25] Paladino JA "Linezolid: an oxazolidinone antimicrobial agent." Am J Health Syst Pharm 59 (2002): 2413-25. [PMID: 12503340]
• [26] Cerner Multum, Inc. "Australian Product Information.".
• [27] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [28] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
• [29] Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
• [30] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
• [31] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
• [32] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [33] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
• [34] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [35] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [36] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [38] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [39] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [40] Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
• [41] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
• [42] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [43] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [44] Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]